- Home
- IMMX vs RLYB Comparison
IMMX vs RLYB Comparison
Compare IMMX & RLYB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMMX
- RLYB
- Stock Information
- Founded
- IMMX 2014
- RLYB 2018
- Country
- IMMX United States
- RLYB United States
- Employees
- IMMX N/A
- RLYB N/A
- Industry
- IMMX Medicinal Chemicals and Botanical Products
- RLYB Biotechnology: Pharmaceutical Preparations
- Sector
- IMMX Health Care
- RLYB Health Care
- Exchange
- IMMX Nasdaq
- RLYB Nasdaq
- Market Cap
- IMMX 51.1M
- RLYB 46.1M
- IPO Year
- IMMX 2021
- RLYB 2021
- Fundamental
- Price
- IMMX $1.66
- RLYB $1.11
- Analyst Decision
- IMMX Strong Buy
- RLYB Buy
- Analyst Count
- IMMX 1
- RLYB 6
- Target Price
- IMMX $7.00
- RLYB $8.30
- AVG Volume (30 Days)
- IMMX 108.3K
- RLYB 49.7K
- Earning Date
- IMMX 11-11-2024
- RLYB 11-07-2024
- Dividend Yield
- IMMX N/A
- RLYB N/A
- EPS Growth
- IMMX N/A
- RLYB N/A
- EPS
- IMMX N/A
- RLYB N/A
- Revenue
- IMMX N/A
- RLYB $299,000.00
- Revenue This Year
- IMMX N/A
- RLYB N/A
- Revenue Next Year
- IMMX $200.00
- RLYB N/A
- P/E Ratio
- IMMX N/A
- RLYB N/A
- Revenue Growth
- IMMX N/A
- RLYB N/A
- 52 Week Low
- IMMX $1.26
- RLYB $1.08
- 52 Week High
- IMMX $7.75
- RLYB $4.60
- Technical
- Relative Strength Index (RSI)
- IMMX 45.76
- RLYB 47.41
- Support Level
- IMMX $1.43
- RLYB $1.09
- Resistance Level
- IMMX $1.94
- RLYB $1.18
- Average True Range (ATR)
- IMMX 0.13
- RLYB 0.04
- MACD
- IMMX -0.01
- RLYB 0.00
- Stochastic Oscillator
- IMMX 57.97
- RLYB 22.22
About IMMX Immix Biopharma Inc.
Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. Its product candidates include CAR-T NXC-201 for autoimmune diseases, and IMX-110 for treatment of soft tissue sarcoma.
About RLYB Rallybio Corporation
Rallybio Corp is a clinical stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare disorders. Its program is for the prevention of fetal and neonatal alloimmune thrombocytopenia, a potentially life-threatening rare disease that can cause uncontrolled bleeding in fetuses and newborns.